Consideration for sale of subsidiary

No definition available.

Name:	evo_ConsiderationForSaleOfSubsidiary
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of enterprise value, calculated on cash and debt free basis.

+ References

No definition available.

+ Details

Name:	evo_EnterpriseValue
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Intercompany loan settlement included in proceeds from disposal of subsidiaries

+ References

No definition available.

+ Details

Name:	evo_IntercompanyLoanSettlementIncludedInProceedsFromDisposalOfSubsidiaries
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liabilities settled, included as a part of consideration on sale of disposal group.

+ References

No definition available.

+ Details

Name:	evo_LiabilitiesSettledConsiderationForDisposalGroup
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Maximum number of biosimilars on which agreement foresees royalties

+ References

No definition available.

+ Details

Name:	evo_MaximumNumberOfBiosimilarsOnWhichAgreementForeseesRoyalties
Namespace Prefix:	evo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

New license agreement license fees to be received

+ References

No definition available.

+ Details

Name:	evo_NewLicenseAgreementLicenseFeesToBeReceived
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

New license agreement upfront license fee received

+ References

No definition available.

+ Details

Name:	evo_NewLicenseAgreementUpfrontLicenseFeeReceived
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The proportion of ownership interest in a subsidiary sold during the period.

+ References

No definition available.

+ Details

Name:	evo_ProportionOfOwnershipInterestInSubsidiarySold
Namespace Prefix:	evo_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of receivables arising from the sale of subsidiaries.

+ References

No definition available.

+ Details

Name:	evo_ReceivablesFromSaleOfSubsidiary
Namespace Prefix:	evo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2025-01-01
-Paragraph 39
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The gains (losses) recognised in association with the loss of control over a subsidiary, which are attributable to the former controlling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph 19
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 81
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 81
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_GainsLossesRecognisedWhenControlInSubsidiaryIsLost
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_LicenceFeeIncome
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_JustEvotecBiologicsEuSasToulouseFranceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=evo_PayableIn60DaysAfterClosingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=evo_PayableInDecember2026Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=evo_PayableOverComingYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS (Details) € in Thousands, $ in Millions			1 Months Ended		12 Months Ended
	Dec. 05, 2025 EUR (€) item	Dec. 05, 2025 USD ($)	Dec. 31, 2025 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2025 EUR (€)	Dec. 31, 2024 EUR (€)	Dec. 05, 2025 USD ($) item
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS
Proceeds from disposal of subsidiaries					€ 222,333	€ (11,503)
Receivable for additional purchase price payment					12,161
Just-Evotec Biologics EU SAS, Toulouse, France
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS
Percentage of ownership interest in subsidiary sold	100.00%	100.00%
Enterprise value	€ 225,000
Purchase price	152,959
Intercompany loans settled by buyer as part of consideration for sale of subsidiary	84,000
Gain (loss) on disposal of subsidiary	€ (3,750)
Licence revenue \| $			$ 108	$ 25
New license agreement upfront license fee received \| $		$ 58
Maximum number of biosimilars on which agreement foresees royalties \| item	10						10
Proceeds from disposal of subsidiaries	€ 222,649
Intercompany loan settlement included in proceeds from disposal of subsidiaries	€ 84,000
Receivable for additional purchase price payment					€ 12,161
Just-Evotec Biologics EU SAS, Toulouse, France \| Payable in 60 days after closing
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS
New license agreement license fees to be received \| $							$ 25
Just-Evotec Biologics EU SAS, Toulouse, France \| Payable in December 2026
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS
New license agreement license fees to be received \| $							25
Just-Evotec Biologics EU SAS, Toulouse, France \| Payable over coming years
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS
New license agreement license fees to be received \| $							$ 300